AT261581T - for designing method and the preparation of ligands zielmolekulbindenden - Google Patents

for designing method and the preparation of ligands zielmolekulbindenden

Info

Publication number
AT261581T
AT261581T AT99119066T AT99119066T AT261581T AT 261581 T AT261581 T AT 261581T AT 99119066 T AT99119066 T AT 99119066T AT 99119066 T AT99119066 T AT 99119066T AT 261581 T AT261581 T AT 261581T
Authority
AT
Austria
Prior art keywords
zielmolekulbindenden
ligands
preparation
designing method
designing
Prior art date
Application number
AT99119066T
Other languages
German (de)
Inventor
Stephen W Fesik
Philip J Hajduk
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US08/555,691 priority Critical patent/US5698401A/en
Application filed by Abbott Lab filed Critical Abbott Lab
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24218250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT261581(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of AT261581T publication Critical patent/AT261581T/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/20Screening for compounds of potential therapeutic value cell-free systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/24Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
AT99119066T 1995-11-14 1996-11-13 for designing method and the preparation of ligands zielmolekulbindenden AT261581T (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/555,691 US5698401A (en) 1995-11-14 1995-11-14 Use of nuclear magnetic resonance to identify ligands to target biomolecules

Publications (1)

Publication Number Publication Date
AT261581T true AT261581T (en) 2004-03-15

Family

ID=24218250

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99119066T AT261581T (en) 1995-11-14 1996-11-13 for designing method and the preparation of ligands zielmolekulbindenden
AT96940448T AT189063T (en) 1995-11-14 1996-11-13 Using nuclear spin resonance for the detection of ligands for binding molecules

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT96940448T AT189063T (en) 1995-11-14 1996-11-13 Using nuclear spin resonance for the detection of ligands for binding molecules

Country Status (14)

Country Link
US (2) US5698401A (en)
EP (2) EP0981049B1 (en)
JP (1) JP3032301B2 (en)
AT (2) AT261581T (en)
AU (1) AU701810B2 (en)
CA (1) CA2237343C (en)
DE (3) DE69606324T3 (en)
DK (1) DK0866967T4 (en)
ES (1) ES2143793T5 (en)
GR (1) GR3032361T3 (en)
IL (2) IL155988A (en)
MX (1) MX9803810A (en)
PT (1) PT866967E (en)
WO (1) WO1997018471A1 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989827A (en) * 1995-11-14 1999-11-23 Abbott Laboratories Use of nuclear magnetic resonance to design ligands to target biomolecules
US20010004528A1 (en) * 1995-11-14 2001-06-21 Stephen W. Fesik Use of 13c nuclear magnetic resonance to detect binding to target molecules
CA2250401A1 (en) 1996-03-29 1997-10-09 Thomas Budinger Enhancement of nmr and mri in the presence of hyperpolarized noble gases
DE19649359C1 (en) * 1996-11-28 1998-02-12 Thomas Prof Dr Peters Detecting biologically active substances in substance libraries
AU772620B2 (en) * 1997-04-18 2004-05-06 Abbvie Inc. Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
US6043024A (en) * 1997-04-18 2000-03-28 Abbott Laboratories Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
WO1998057155A1 (en) * 1997-06-13 1998-12-17 Vertex Pharmaceuticals Incorporated Methods for identifying drug cores
US20030143757A1 (en) * 1997-06-13 2003-07-31 Jonathan Moore Methods for identifying drug cores
US6111066A (en) 1997-09-02 2000-08-29 Martek Biosciences Corporation Peptidic molecules which have been isotopically substituted with 13 C, 15 N and 2 H in the backbone but not in the sidechains
US6344330B1 (en) * 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
US20020131972A1 (en) * 1998-05-21 2002-09-19 Daniel Sem Multi-partite ligands and methods of identifying and using same
CA2319495A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
IL143927D0 (en) * 1998-12-30 2002-04-21 Nycomed Amersham Plc Nmr spectroscopic in vitro assay using hyperpolarization
US6897337B2 (en) * 1999-04-09 2005-05-24 Abbott Laboratories Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors therefor
TWI283659B (en) * 1999-04-09 2007-07-11 Abbott Lab Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors therefor
US6333149B1 (en) * 1999-06-04 2001-12-25 Triad Biotechnology, Inc. NMR-solve method for rapid identification of bi-ligand drug candidates
US6171804B1 (en) 1999-07-12 2001-01-09 The Rockefeller University Method of determining interdomain orientation and changes of interdomain orientation on ligation
US7105310B1 (en) * 2000-07-19 2006-09-12 California Institute Of Technology Detection of biomolecules by sensitizer-linked substrates
WO2001006260A1 (en) * 1999-07-19 2001-01-25 California Institute Of Technology Detection of biomolecules by sensitizer-linked substrates
AU6937100A (en) * 1999-08-23 2001-03-19 Polaris Pharmaceuticals, Inc. Inhibitors of binding between proteins and macromolecular ligands
US6677160B1 (en) 1999-09-29 2004-01-13 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
US6764858B2 (en) 1999-09-29 2004-07-20 Pharmacia & Upjohn Company Methods for creating a compound library
WO2001023889A1 (en) * 1999-09-29 2001-04-05 Smithkline Beecham Corporation Method of using one-dimensional and multi-dimensional nuclear magnetic resonance to identify compounds that interact with target biomolecules
WO2001023330A2 (en) * 1999-09-29 2001-04-05 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
GB9925677D0 (en) * 1999-10-29 1999-12-29 Pharmacia & Upjohn Spa Use of double-quantum 1H-NMR spectroscopy for the identification of ligands interacting with target biomolecules
BR0108606A (en) * 2000-02-25 2003-01-07 Wyeth Corp Drug planning methods based on the structure employing in / nmr
WO2001079852A2 (en) * 2000-04-17 2001-10-25 Pharmacia & Upjohn Company Nmr-methods for indentifying sites in papillomavirus e2 protein
GB0013115D0 (en) * 2000-05-31 2000-07-19 Imp College Innovations Ltd Biological materials and methods for use in the prevention or treatment of infections
US7146277B2 (en) * 2000-06-13 2006-12-05 James H. Prestegard NMR assisted design of high affinity ligands for structurally uncharacterized proteins
US20030165431A1 (en) * 2000-07-13 2003-09-04 The Regents Of The University Of California Method for detecting macromolecular conformational change and binding information
US7061237B2 (en) * 2000-07-13 2006-06-13 The Regents Of The University Of California Remote NMR/MRI detection of laser polarized gases
US6652833B2 (en) 2000-07-13 2003-11-25 The Regents Of The University Of California Functionalized active-nucleus complex sensor
US8173441B2 (en) 2000-09-27 2012-05-08 Universiteit Leiden Method for applying NMR for ligand discovery or as a drug screening tool
SE0003811D0 (en) * 2000-10-20 2000-10-20 Pharmacia Ab screening Methods
AU5655602A (en) * 2000-12-21 2002-07-01 Triad Therapeutics Inc Sea-trosy and related methods
DE60120494T2 (en) * 2000-12-22 2006-12-21 Ortho-Mcneil Pharmaceutical, Inc. Substituieten triazoldiamin derivatives and their use as kinase inhibitors
US6656694B2 (en) 2001-01-11 2003-12-02 Theravance, Inc. Method for identifying a ligand for a biological substrate
US7645569B2 (en) * 2001-01-26 2010-01-12 Board Of Regents, The University Of Texas System NMR detection of foreign PAS domain ligands
US20020172967A1 (en) * 2001-02-13 2002-11-21 Gadek Thomas R. Identification of non-covalent complexes by mass spectrometry
DE10119455B4 (en) * 2001-04-20 2010-12-16 Siemens Ag A method of evaluating data that are generated by the magnetic resonance technique and includes spectroscopic information
PT1401853E (en) 2001-05-25 2010-12-07 Univ Duke Modulators of pharmacological agents
AU2002312146A1 (en) * 2001-05-30 2002-12-09 Triad Therapeutics, Inc. Nuclear magnetic resonance-docking of compounds
US20030129672A1 (en) * 2001-08-29 2003-07-10 Dyer Richard Dennis Method for identifying metalloenzyme inhibitors
US7653490B2 (en) * 2001-09-10 2010-01-26 Triad Liquidating Company LLC Nuclear magnetic resonance assembly of chemical entities
DE10144661C2 (en) * 2001-09-11 2003-08-14 Forschungsverbund Berlin Ev Apparatus and method for assignment of the NMR signals of polypeptides
US7179450B2 (en) * 2001-09-20 2007-02-20 Medi-Physics, Inc. Methods for in vivo evaluation of pulmonary physiology and/or function using NMR signals of polarized Xe
US7037660B2 (en) * 2001-11-06 2006-05-02 Message Pharmaceuticals Methods for detecting and quantifying binding and inhibition of binding of species to nucleic acids
DE10160177A1 (en) * 2001-12-07 2003-06-26 Novaspin Biotech Gmbh Location of ligands for bonding to a given drug target, comprises using NMR with a reference and a test spectrum, to assess changes in the drug target signals without using isotopes for marking
US20040171062A1 (en) * 2002-02-28 2004-09-02 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
US20030180797A1 (en) * 2002-03-20 2003-09-25 Lin Yu Identification of ligands for a receptor family and related methods
AU2003253589A1 (en) * 2002-03-26 2003-11-10 Centocor, Inc. Epitope mapping using nuclear magnetic resonance
DE10221158A1 (en) * 2002-05-13 2004-02-19 Novaspin Biotech Gmbh Method for identifying ligands that bind to a drug target, by heteronuclear NMR spectroscopy
EP1551291A4 (en) * 2002-06-10 2007-11-28 Prospect Pharma Method for obtaining dynamic and structural data pertaining to proteins and protein/ligand complexes
WO2006078228A1 (en) * 2002-09-16 2006-07-27 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
AU2003272548A1 (en) * 2002-09-16 2004-04-30 Plexxikon, Inc. Crystal structure of pim-1 kinase
US20040132102A1 (en) * 2002-10-29 2004-07-08 Maurizio Pellecchia Use of selective labeling to detect and characterize molecular interactions by nuclear magnetic resonance spectroscopy
NO20025738D0 (en) * 2002-11-29 2002-11-29 Amersham Health As Method
EP1627045A2 (en) * 2003-02-28 2006-02-22 Plexxikon, Inc. Pyk2 crystal structure and uses
WO2004083814A2 (en) * 2003-03-13 2004-09-30 Triad Therapeutics, Inc. Nuclear magnetic resonance assembly of chemical entities using advanced antenna probes
US20040265909A1 (en) * 2003-04-11 2004-12-30 Jeff Blaney Compound libraries and methods for drug discovery
EP1617221A4 (en) * 2003-04-23 2006-08-02 Olympus Corp Method for screening substance which can bind to receptor
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US7255985B2 (en) * 2003-07-10 2007-08-14 Pfizer Italia S.R.L. Fluorine NMR spectroscopy for biochemical screening
WO2005028624A2 (en) * 2003-09-15 2005-03-31 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
US20070275442A1 (en) * 2003-10-07 2007-11-29 Prospect Pharma Side Chain Deuterated Amino Acids Methods Of Use
JP4192078B2 (en) * 2003-11-26 2008-12-03 株式会社日立製作所 Nuclear magnetic resonance method
WO2005052620A1 (en) * 2003-11-28 2005-06-09 Hitachi, Ltd. Method of identifying agonist and antagonist for target protein with use of nuclear magnetic resonance technique, and program for use in the method
GB0405330D0 (en) * 2004-03-10 2004-04-21 Astrazeneca Ab Enzyme and preparation method
EP1794324A4 (en) 2004-09-20 2010-04-14 Wisconsin Alumni Res Found Nonlinear spectroscopic methods for identifying and characterizing molecular interactions
JPWO2006082963A1 (en) * 2005-02-07 2008-06-26 三菱化学株式会社 Coupling method of detecting a target molecule and the ligand or ligand candidate compound
EP2013624B1 (en) 2006-03-14 2011-08-03 Universität Basel Method for the identification of new leads for drug candidates
US8933209B2 (en) 2006-04-26 2015-01-13 Abbvie Inc. Dep2 and its uses in major depressive disorder and other related disorders
US7760342B2 (en) 2007-12-21 2010-07-20 Wisconsin Alumni Research Foundation Multidimensional spectrometer
WO2012108297A1 (en) * 2011-02-07 2012-08-16 国立大学法人 神戸大学 AQUEOUS SOLUTION CONTAINING PARTIAL RaS POLYPEPTIDE AND METHOD FOR SCREENING INHIBITOR OF RaS FUNCTION
KR101855242B1 (en) 2012-01-26 2018-05-09 크리스토퍼 제이. 소레스 Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991010140A2 (en) * 1989-12-29 1991-07-11 University Technologies International Inc. Methods for modelling tertiary structures of biologically active ligands including agonists and antagonists thereto and novel synthetic antagonists based on angiotensin
US5164297A (en) * 1990-05-03 1992-11-17 Advanced Magnetics Inc. Solvent mediated relaxation assay system
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
AU655839B2 (en) * 1991-06-27 1995-01-12 Genelabs Technologies, Inc. Screening assay for the detection of DNA-binding molecules
US5726014A (en) * 1991-06-27 1998-03-10 Genelabs Technologies, Inc. Screening assay for the detection of DNA-binding molecules

Also Published As

Publication number Publication date
DE69606324T2 (en) 2000-07-06
CA2237343A1 (en) 1997-05-22
EP0866967A1 (en) 1998-09-30
DE69606324T3 (en) 2008-02-07
IL155988A (en) 2005-07-25
EP0866967B1 (en) 2000-01-19
IL155988D0 (en) 2003-12-23
EP0981049B1 (en) 2004-03-10
AU7732896A (en) 1997-06-05
US5698401A (en) 1997-12-16
DK0866967T4 (en) 2007-12-10
MX9803810A (en) 1998-09-30
EP0866967B2 (en) 2007-08-08
GR3032361T3 (en) 2000-04-27
AU701810B2 (en) 1999-02-04
DE69606324D1 (en) 2000-02-24
ES2143793T3 (en) 2000-05-16
ES2143793T5 (en) 2008-03-01
IL123923A (en) 2005-07-25
WO1997018471A1 (en) 1997-05-22
CA2237343C (en) 2009-01-20
US5804390A (en) 1998-09-08
JPH11513498A (en) 1999-11-16
DK0866967T3 (en) 2000-06-26
JP3032301B2 (en) 2000-04-17
AT189063T (en) 2000-02-15
EP0981049A1 (en) 2000-02-23
DE69631842D1 (en) 2004-04-15
PT866967E (en) 2000-04-28

Similar Documents

Publication Publication Date Title
DE69417025T2 (en) nonwoven shaped and process for its manufacture
DE69527636T2 (en) Stent and process for its manufacture
DE69814454D1 (en) Composite material having elasticized portions and process for its preparation
DE69424669D1 (en) The absorbent composite material and process for its preparation
DE69432327D1 (en) Together Gesetzer photocatalyst and method for its preparation
AT158788T (en) A process for the preparation of amines
DE69532565D1 (en) A process for the preparation of 2'-isoguanosine and derivatives thereof
DE69513421T2 (en) polytetrafluoroethylenfilm porous and process for its manufacture
DE69804768T2 (en) Fernsteuerinrichtung and method thereof
DE69418484D1 (en) nonwoven Rippenstoffaenliche and method for manufacturing
DE69608880D1 (en) Kit and method
DE69505112T2 (en) Device and method for the manufacture of plasterboard
DE69533594D1 (en) Preparations and methods for triggering of ctl-immunity
DE69623460D1 (en) A process for the preparation of 3-haloalkyl-1H-pyrazoles
DE69530954D1 (en) Micromechanical component thereof and methods for preparing
DE69417218D1 (en) Glove and process for its manufacture
DE69528322T2 (en) Reactor and process for its preparation
DE69528111D1 (en) the same biosensor and method for preparing
DE69715738T2 (en) Reifenvulkanisierungsformwerkzeug and process for its preparation
DE69603580D1 (en) Photocatalyst and method for manufacturing
DE69120892T2 (en) Gleitschutzhandschuh and process for its preparation
DE69504075T2 (en) Highly effective metallverbundstoffmembrangetterelement and process for production thereof
AT187095T (en) Catalytic compositions and methods for deodorize so
DE69530767D1 (en) Decal and method for its manufacture
AT251627T (en) Method, and crystal form of 2- methylthienobenzodiazepinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties